Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 2020

View Archived Issues

FDA clears IND application for TTX-080

Seelos initiates preclinical testing of SLS-007 in Parkinson's disease

Positive phase I/IIa results presented for AIV-001 in dermal scarring

New phase IIa study evaluates BO-112 with pembrolizumab for liver metastases

Janssen discontinues phase III LOTUS study of ustekinumab in SLE

Sunshine Lake Pharma discovers RET inhibitors

Reblozyl approved in Europe for transfusion-dependent anemia in MDS or beta-thalassemia

Discovery and preclinical characterization of novel dual inhibitor of LSD1-HDAC6, JBI-802

New muscarinic M1 and/or M4 receptor agonists presented by Heptares Therapeutics

Next-generation ONCOS oncolytic adenovirus tested in melanoma mouse models

Boehringer Ingelheim identifies new pantetheinase inhibitors

Cornell University patents IRE1 inhibitors

New Nav1.7 channel blockers identified at Merck & Co.

First-in-human data presented for YG-1699

P53 'glue' gums up cancer cells

Ferrets and cats, but not dogs, pigs, chickens or ducks, are susceptible to SARS-CoV-2 infection

Benzoselenoxanthenes targeting TMPRSS2 gene G-quadruplex inhibit influenza A virus propagation

Results of the first phase I trial evaluating a mosquito salivary peptide-based vaccine

Next-generation anti-claudin18.2 antibody NBL-015 for gastric and pancreatic cancer

In-brain direct reprogramming creates neurons, alleviates Parkinson's

FDA approves Mycapssa for long-term maintenance treatment in patients with acromegaly

Japanese approval of Rybelsus for type 2 diabetes

European Commission approves Ultomiris for adults and children with aHUS

Oblique Therapeutics and Targovax to combine platforms to target mutant RAS cancers

ReNeuron reports further data from phase IIa study of hRPC stem cell therapy candidate in RP

Japan first to approve Duvroq for anemia due to chronic kidney disease

Celltex cleared to begin phase II study of AdMSCs against COVID-19

Novartis obtains five approvals from Japanese MHLW

Zucero's pixatimod demonstrates antiviral activity against SARS-CoV-2 in laboratory studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...